Is multiple sclerosis progression associated with the HLA-DR15 haplotype? by Stürner, Klarissa Hanja et al.








Is multiple sclerosis progression associated with the HLA-DR15 haplotype?
Stürner, Klarissa Hanja ; Siembab, Inessa ; Schön, Gerhard ; Stellmann, Jan-Patrick ; Heidari, Nika ;
Fehse, Boris ; Heesen, Christoph ; Eiermann, Thomas H ; Martin, Roland ; Binder, Thomas M C
Abstract: Background The prevalence of multiple sclerosis is associated with the major histocompatibil-
ity complex class II DR15 haplotype HLA-DRB1*15:01฀HLA-DRB5*01:01. Objective To assess whether
multiple sclerosis progression is associated with the main susceptibility haplotype HLA-DRB1*15:01฀HLA-
DRB5*01:01. Methods Patients (n = 1230) and healthy controls (n = 2110) were genotyped for HLA-
DRB1 and HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined
and patients were followed for at least 3 years. Results After follow-up of the consecutive cohort 349
patients were classified as having clinical isolated syndrome and 881 patients as having multiple sclerosis.
The susceptibility allele HLA-DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio
1.56) and multiple sclerosis (odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only
enriched HLA-DRB1 allele in multiple sclerosis patients. Comparison of clinical characteristics between
HLA-DRB1*15:01฀HLA-DRB5*01:01 negative and positive patients with multiple sclerosis showed that
baseline EDSS score, disease duration and frequency of the category secondary progressive multiple scle-
rosis with relapse were increased in the HLA-DRB1*15:01฀HLA-DRB5*01:01 positive group. Conclusion
The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility alleles and
showed weak indirect evidence for a role in progression of the disease.
DOI: https://doi.org/10.1177/2055217319894615






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Stürner, Klarissa Hanja; Siembab, Inessa; Schön, Gerhard; Stellmann, Jan-Patrick; Heidari, Nika; Fehse,
Boris; Heesen, Christoph; Eiermann, Thomas H; Martin, Roland; Binder, Thomas M C (2019). Is
multiple sclerosis progression associated with the HLA-DR15 haplotype? Multiple Sclerosis Journal –
Experimental, Translational and Clinical, 5(4):205521731989461.
DOI: https://doi.org/10.1177/2055217319894615
Original Research Paper
Is multiple sclerosis progression associated with
the HLA-DR15 haplotype?
Klarissa Hanja Stürner , Inessa Siembab, Gerhard Sch€on, Jan-Patrick Stellmann, Nika Heidari,
Boris Fehse, Christoph Heesen , Thomas H Eiermann , Roland Martin and Thomas MC Binder
Abstract
Background: The prevalence of multiple sclerosis is associated with the major histocompatibility
complex class II DR15 haplotype HLA-DRB1*15:01HLA-DRB5*01:01.
Objective: To assess whether multiple sclerosis progression is associated with the main susceptibility
haplotype HLA-DRB1*15:01HLA-DRB5*01:01.
Methods: Patients (n¼ 1230) and healthy controls (n¼ 2110) were genotyped for HLA-DRB1 and
HLA-DRB5. The baseline Expanded Disability Status Scale (EDSS) score was determined and patients
were followed for at least 3 years.
Results: After follow-up of the consecutive cohort 349 patients were classified as having clinical
isolated syndrome and 881 patients as having multiple sclerosis. The susceptibility allele HLA-
DRB1*15:01 was more frequent in clinical isolated syndrome (odds ratio 1.56) and multiple sclerosis
(odds ratio 3.17) compared to controls. HLA- DRB1*15:01 was the only enriched HLA-DRB1 allele in
multiple sclerosis patients. Comparison of clinical characteristics between HLA-DRB1*15:01HLA-
DRB5*01:01 negative and positive patients with multiple sclerosis showed that baseline EDSS score,
disease duration and frequency of the category secondary progressive multiple sclerosis with relapse
were increased in the HLA-DRB1*15:01HLA-DRB5*01:01 positive group.
Conclusion: The study confirmed HLA-DRB1*15:01 and HLA-DRB5*01:01 as the main susceptibility
alleles and showed weak indirect evidence for a role in progression of the disease.
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Introduction
Multiple sclerosis (MS) is a debilitating autoimmune
disease of the central nervous system predominantly
in women and is caused by the combination of a
complex genetic background and environmental trig-
ger factors.1,2 The greatest individual genetic risk is
conferred by the major histocompatibility complex
(MHC) or human leukocyte antigen (HLA)-DR15
haplotype, which contains the two DRB alleles
HLA-DRB1*15:01 and HLA-DRB5*01:01 in virtu-
ally 100% linkage disequilibrium.3,4 Based on data
from many studies, the HLA-DR15 haplotype is now
considered to confer, in Caucasians, up to 60% of
the MS disease risk, while the known non-MHC risk
markers account for approximately 20%.5–7 The two
DR antigens generated by the HLA-DR15 haplotype
are the heterodimer of HLA-DRA1*01:01/HLA-
DRB1*15:01, also referred to as DR2b and the het-
erodimer of HLA-DRA1*01:01/HLA-DRB5*01:01,
also referred to as DR2a.8 This short HLA haplotype
is part of the complete HLA-DR15 haplotype (HLA-
DRA1*01:01HLA-DRB5*01:01HLA-DRB1*
15:01HLA-DQA1*01:02HLA-DQB1*06:02).
Furthermore, it has been shown that the impact of
important environmental risk factors for MS
(Epstein–Barr virus infection, cigarette smoking
and low vitamin D3 serum level) is increased in
HLA-DR15 haplotype carriers in a more than
additive fashion.2,9
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Various approaches have been pursued to assess the
impact of the HLA-DR15 haplotype on disease pro-
gression, as reviewed by van der Walt et al.10 In
eight of 18 studies, no effect of the HLA-DR15 hap-
lotype was seen, in six of 18 younger ages at diag-
nosis (onset) were reported, and in four of 18
marginally worse EDSS outcome was observed.
The few studies that report an influence showed a
protective effect of the HLA-DRB1*04 and the
HLA-DRB1*01/HLA-DRB1*15 allele combination
for the primary-progressive course,11 an earlier con-
version of HLA-DR15 carriers to secondary progres-
sive multiple sclerosis (SPMS),12 and a worse
disease outcome.13 HLA-DR15 and HLA-DR4
were associated with relapsing–remitting multiple
sclerosis (RRMS) and SPMS, while primary pro-
gressive multiple sclerosis (PPMS) was additionally
related to HLA-DR4/HLA-DQw8, HLA-DR7/HLA-
DQw9 and HLA-DRw8/HLA-DQw4 haplotypes.14
Numerous pharmacogenomic studies have explicitly
examined the effect of HLA-DR allele status as well
as other genes on treatment response of first-line
therapies in MS. To date all have concluded that
neither HLA-DR15 nor any other HLA allele
showed an association with response to either
interferon-beta or glatiramer acetate treatment
(reviewed in Mahurkar et al.)15
In this study we examined a large cohort of consec-
utive patients referred to a northern German centre
for MS to address whether the HLA-
DRB1*15:01HLA-DRB5*01:01 haplotype is asso-
ciated with clinical progression.
Methods
Study subjects
A total of 1230 consecutive individuals was
recruited between 1994 and 2010 at the MS outpa-
tient unit and day care clinic of the University
Medical Center Hamburg-Eppendorf, typed for
HLA, and clinically evaluated at each visit; 2110
ethnically matched platelet and stem cell donors
recruited between 1995 and 2010 at the
Department of Transfusion Medicine served as con-
trols. The local ethics committee (Ethik-
Kommission der €Arztekammer Hamburg) approved
the study (no. 2758) and written informed consent
was obtained from all subjects.
HLA genotyping
DNA was extracted from ethylenediamine tetraace-
tic acid blood as described previously.16 Samples
were typed for HLA class II (DRB1 and DRB5)
using the reverse sequence specific oligonucleotide
dotblot method. Exon 2 for both genes was amplified
and interrogated.17–19 Helmberg-Score software was
used for allelic assignment in cooperation with the
most recent nomenclature report and library.20,21
Remaining ambiguities were resolved to two-field
allele resolution (DRB1) by sequencing of
amplimers obtained after sequence-specific poly-
merase chain reaction with appropriate primers
(Olerup/CareDx, Stockholm, Sweden).
Clinical evaluation
Clinical tests comprised the symbol digit modality
test, 9-hole-peg-test, timed 25-footwalk and timed
tandem walk, which were performed at each clinical
visit. Performance was rated by the EDSS.22 In
Kaplan–Meier analysis, the time interval to progress
from an EDSS score below 4 to an EDSS score
below 9 served as the clinical endpoint.
Statistical analysis
Allele carrier frequencies were calculated by gene
counting.23 The control cohort was in Hardy–
Weinberg equilibrium (see Supplementary Table
1). Odds ratios (ORs) were calculated to measure
MS risk. Significance was evaluated by two-sided
t-test for continuous variables and Fisher’s exact
test or Pearson test for categorical variables.
Kaplan–Meier curves were tested by log-rank and
hazard ratios by likelihood ratio. Values of P0.05
were considered statistically significant. P values
were corrected when appropriate.
Results
Follow-up of the consecutive cohort of 1230 patients
revealed that 349 patients had clinically isolated
syndrome (CIS) and 881 patients had MS (Table
1). The phenotypic frequency of the MS susceptibil-
ity allele HLA-DRB1*15:01 increased from 26.7%
in controls to 38.0% in CIS and 53.8% in MS. A
similar increase was seen for HLA-DRB5*01:01
from 26.5% in controls to 53.0% in MS (see
Supplementary Table 2). The HLA-DRB1*15 allelic
group was the only one to be singled out as enriched
in MS over controls (Figure 1). Significantly under-
represented HLA-DRB1 allelic groups were HLA-
DRB1*07, 08, 11, 13 and 14. After Bonferroni
correction only the HLA-DRB1*01 group remained
significantly reduced, which reflects the smaller
confidence interval of the OR and the higher preva-
lence of this group in German Caucasians as
compared with, for example, the HLA-DRB1*09
group. To address further the status of these ‘alter-
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the DRB1*15:01 carrier status (see Supplementary
Table 3). This analysis revealed no significant
protective effect of any DRB1 allelic group in the
non-DRB1*15:01 carriers except for the DRB1*07
allelic group. However, the effect was weak (OR
0.71) and not significant when corrected for multiple
comparisons. Interestingly, DRB1*07 was signifi-
cantly increased in the DRB1*15:01 carriers (OR
2.60) and this remained significant after Bonferroni
correction. Thus the highest MS risk was observed in
DRB1*15:01, 07 heterozygotes (OR 5.05).
Next we compared the clinical characteristics between
HLA-DRB1*15:01 negative and positive patients with
MS to look for confounding variables (Table 2). There
was no difference in age, sex and frequency of MS
categories between the two groups. Significant but
small differences were observed for higher baseline
EDSS scores and longer disease duration in
the HLA-DRB1*15:01HLA-DRB5*01:01 positive
group. To analyse further the trend seen for SPMS
we compared the frequency of MS categories and sub-
categories (Table 3). Here again an increased frequen-
cy of relapsing SPMS was observed for the HLA-
HLA-DRB1*15:01HLA-DRB5*01:01 positive
group.
In 669 patients with MS and complete neurological
examination, the distribution of low (0–4.5) and high
(5–8.5) baseline EDSS scores correlated with the
MS category (Table 4) and the presence of HLA-
DRB1*15:01HLA-DRB5*01:01 (Table 5). MS
patients with high-level baseline EDSS scores were
more frequently positive for the susceptibility HLA-
DRB1*15:01HLA-DRB5*01:01 haplotype. It is of
note that SPMS with relapse stands out with the
highest baseline EDSS (Table 4), which in turn
will reduce the probability of further increasing in
follow-up. To correct for this we decided to use the
time for change from the lower EDSS score group to
Table 1. HLA-DRB1*15:01 allele and phenotypic frequencies in multiple sclerosis, CIS and German controls.
N Allele frequency Phenotypic frequency Odds ratio P value
Multiple sclerosis 881 0.308 0.538 3.17 <0.0001
CIS 349 0.212 0.380 1.56 0.0003
Control subjects 2110 0.146 0.267 – –
CIS: clinically isolated syndrome.
Figure 1. Forrest plot of odds ratios (ORs) for multiple sclerosis (MS) risk according to HLA-DRB1 allelic group. HLA-DRB1*15 risk group in
red, neutral allelic groups (*03, *04, *09, *10, *12, *16) in yellow, underrepresented and potentially protective allelic groups (*07, *08, *11, *13,
*14) in green. OR and 95% confidence intervals (CIs); Bonferroni corrected P (pcor).
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the higher EDSS score group as the clinical endpoint
in Kaplan–Meier analysis.
Kaplan–Meier analysis for disease progression from
baseline EDSS score less than 4 (0–3.5) to EDSS
score less than 9 (4–8.5) confirmed most of these
findings (Figure 2). While disease progression
occurred in 25% of the cases after 8.9 years in
RRMS, this happened in PPMS and SPMS after
3.4 and 2.3 years, respectively (Figure 2(a)).
The univariate hazard ratio for progression
between SPMS versus RRMS was 3.6 (95%
CI 2.4–5.5). Men had a higher risk of progression
than women (Figure 2(b)), with a univariate
hazard ratio of 1.5 (95% CI 1.1–2.1). The presence
of HLA-DRB1*15:01HLA-DRB5*01:01 had
Table 2. Comparison of clinical characteristics between HLA-DRB1*15:01 negative and positive patients
with multiple sclerosis.
Negative (N¼408) Positive (N¼ 473) P value
Age (years; mean, SD) 45 11 46 10 0.06
Sex (female) 66% 71% 0.17
Baseline EDSS score (mean, SD) 2.9 1.8 3.2 2.0 0.049
Disease duration (years; mean, SD) 13 9 15 9 0.046
Age at onset (years; mean, SD) 32 11 32 10 1.00
Relapsing–remitting MS 68% 64% 0.18
Primary progressive MS 14% 13% 0.85
Secondary progressive MS 18% 23% 0.08
Two-sided t-test for continuous variable, Fisher’s exact test for categorical variable, uncorrected P.
EDSS: Expanded Disability Status Scale; MS: multiple sclerosis.
Note. Bold value represents P  0.05.
Table 3. Multiple sclerosis category and DRB1*15:01 status (N¼881).
Category Negative Positive P value Pcor.
Relapsing–remitting MS without residue 189 (46%) 188 (40%) 0.06 0.36
Relapsing–remitting MS with residue 89 (22%) 113 (24%) 0.47
Primary progressive MS without relapse 38 (9%) 47 (10%) 0.82
Primary progressive MS with relapse 19 (5%) 17 (3%) 0.50
Secondary progressive MS without relapse 36 (9%) 39 (8%) 0.81
Secondary progressive MS with relapse 37 (9%) 69 (15%) 0.013 0.078
Fisher’s exact test, Bonferroni corrected P (Pcor.).
MS: multiple sclerosis.
Note. Bold value represents P  0.05.
Table 4. Multiple sclerosis category and baseline EDSS groups (total N¼669).
Category N Low (0–4.5) High (5–8.5) P value
Relapsing–remitting MS without residue 294 98% 2% 1.0 10–38
Relapsing–remitting MS with residue 134 90% 10%
Primary progressive MS without relapse 71 62% 38%
Primary progressive MS with relapse 29 66% 34%
Secondary progressive MS without relapse 63 64% 36%
Secondary progressive MS with relapse 78 39% 61%
Pearson test.
MS: multiple sclerosis.
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no effect on progression, either in the combined data
(Figure 2(c)) or in the RRMS subset (Figure 2(d)), as
well as the PPMS and SPMS subsets (data not
shown).
Discussion
The analysis of this single-centre northern German
MS patient cohort confirmed that HLA-
DRB1*15:01 and HLA-DRB5*01:01 are the most
prominent MS risk alleles. The finding of an enrich-
ment of HLA-DRB1*15:01 and HLA-DRB5*01:01
in CIS and MS, the higher baseline EDSS scores
and longer disease duration in the HLA-
DRB1*15:01HLA-DRB5*01:01 positive group
suggests that the HLA-DRB1*15:01DRB5*01:01
haplotype weakly influences the clinical progression
of MS. However, this could not be confirmed in the
Kaplan–Meier analysis for progression.
Despite its long and well-known association with
MS, the mechanism by which HLA-DR15 confers
disease susceptibility is not yet understood. Recent
data indicate increased T-cell proliferation in MS
patients carrying the HLA-DR15 allele24 and an
increased risk of the presence of oligoclonal bands
Table 5. Baseline Expanded Disability Status Scale (EDSS) groups and HLA-DRB1*15:01 status.
EDSS N DRB1*15:01 negative DRB1*15:01 positive P value
Low (0–4.5) 542 48% 52% <0.04
High (5–8.5) 127 39% 61%
Fisher’s exact test.
Figure 2. Kaplan–Meier plots of Expanded Disability Status Scale (EDSS) progression stratified for (a) multiple sclerosis (MS) category, (b) sex,
(c) HLA-DRB1*15:01 status in the total cohort (N¼ 434) and (d) in the subset of patients with relapsing–remitting multiple sclerosis (RRMS).
PPMS, primary progressive MS; SPMS, secondary progressive MS.
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in the cerebrospinal fluid,25 nevertheless further
studies are needed to shed light on the underlying
mechanism and its potential modulation by environ-
mental factors. Environmental agents such as vita-
min D, viral infections, diet and noxious agents2
have been reported to contribute to MS risk in gen-
eral, and in the case of cigarette smoking9 and obe-
sity26 to enhance MS risk synergistically in
combination with HLA-DR15. Cigarette smoking
has recently also been associated with a worse dis-
ease outcome in EDSS parameters.27 The impact of
vitamin D on the clinical course of MS has yet to be
examined in clinical studies. Following the hypoth-
esis of a disease-relevant expression of an alternative
vitamin D response element (VDRE) in the promoter
region of HLA-DR15 allele carriers, it has been sug-
gested that a vitamin D deficiency in early life or in
utero allows autoreactive T cells of HLA-DR15
allele carriers to escape central thymic deletion.
Nolan and colleagues showed the presence of the
constant VDRE in all HLA-DRB1 alleles yet they
discussed the potentially protective effect on MS
risk in HLA-DRB1*04, *07, *09 (DR53 group)
allele carriers attributable to the non-responsive
VDRE motif that they had detected in these alleles.28
In contrast to these studies we did not observe a
protective effect of the DR53 group associated
alleles in our cohort, as only HLA-DRB1*07
showed a trend for underrepresentation in our MS
patient cohort. HLA-DRB1*04 showed an equal dis-
tribution in controls and MS patients and only a few
cases in our cohort were HLA-DRB1*09 carriers
leading to a wide CI. In conclusion, there was no
single dominant protective HLA-DRB1 group.
The influence of pairs of classic HLA alleles in
strong linkage disequilibrium, HLA-
DRB1*15:01HLA-DQB1*06:02 and HLA-
DRB1*01:01HLA-DQA1*01:01, on age at onset
has recently been shown in a large cohort.29 In addi-
tion, evidence for a strong protective effect of HLA-
DQA1*01:01 in the presence of HLA-DRB1*15:01
and an allelic interaction between HLA-
DQB1*03:01 with HLA-DQB1*03:02 was found.
Re-examining our cohort of MS patients, we found
HLA-DQA1*01:01 in combination with HLA-
DRB1*15:01 in 39 of 881 patients and HLA-
DQB1*03:01 with HLA-DQB1*03:02 in 18 of 881
patients. Further statistical analysis showed no sig-
nificant correlation with age of onset or clinical out-
come parameter in these patient subgroups. With
respect to magnetic resonance imaging lesion load
and histopathological findings, more extensive CNS
inflammation has been described in HLA-DR15
haplotype carriers based on small MS cohorts30
and recently also in PPMS.31 However, these data
have not been confirmed in larger cohorts.32,33
In the era of disease-modifying therapy (DMT) for
MS, it has become even more difficult to assess dis-
ease progression (i.e. Kaplan–Meier analysis using
an increase in EDSS as a clinical endpoint). This is
because, along with possible effects of the DMT, the
baseline EDSS is highly associated with the MS cat-
egory. Therefore analysis must be stratified accord-
ingly, which reduces the power of the present study
by reducing the total N from originally 1230 subjects
to 434 subjects, who showed EDSS score-
progression (Figure 2(a)–(c)) to 272 subjects with
RRMS (Figure 2(d)). Under these circumstances,
we have no direct evidence for an impact of HLA-
DRB1*15:01HLA-DRB5*01:01 on disease pro-
gression. We predict that, if the indirect evidence
we see were to become manifest in a larger prospec-
tive study controlled for DMT, the effect would be
weak, approximately in the range of the effect seen
for the gender. In conclusion, apart from MS cate-
gory and patient sex we could not identify HLA-
DRB1*15:01HLA-DRB5*01:01 as a predictor for
clinical progression.
Although this is the largest single-centre MS patient
cohort to be evaluated for the HLA-
DRB1*15:01HLA-DRB5*01:01 haplotype as a
biomarker to predict clinical progression,10,33 the
study is limited by its retrospective design and lack
of data on HLA class I and non-MHC modifying
markers. In particular, the impact of the protective
HLA-A*02:01 allele34 and the risk-increasing HLA-
A*03:01 allele, as well as the presence of other
recently identified MS-relevant genes are not includ-
ed.6 It remains unclear to what extent these genes,
alone or in combination, contribute to disease pro-
gression. Finally, due to the retrospective design and
lack of a mandatory schedule for clinical follow-up,
we cannot exclude a bias towards worse disease
development as patients with more severe disease
activity are more likely to visit the centre more
frequently.
Conclusions
For a northern European group, we here confirm the
HLA-DRB1*15:01HLA-DRB5*01:01 haplotype
as the single most influential disease susceptibility
marker in MS and show evidence for its weak
impact on clinical disease progression.
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